Development and validation of dissolution tests of fexofenadine hydrochloride capsules and coated tablets

Journal of Pharmacy and Pharmaceutical Sciences

Volumn 8, Issue 2, 2005, Pages 289-298

  Breier, Ana R ^a   Paim, Clésio S ^a   Steppe, Martin ^a   Schapoval, Elfrides E S ^a  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

FEXOFENADINE;

ARTICLE; CONTROLLED STUDY; DRUG CAPSULE; DRUG DOSAGE FORM; DRUG RELEASE; DRUG SOLUBILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; TABLET; VALIDATION PROCESS;

CAPSULES; CHEMISTRY, PHARMACEUTICAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; SOLUBILITY; TABLETS, ENTERIC-COATED; TERFENADINE;

EID: 27244459294     PISSN: 14821826     EISSN: 14821826     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. The Merck Index, an Encyclopedia of Chemicals, Drugs, and Biologicals. Merck & CO., INC. Whitehouse Station, NJ, 2001.
2. Simpson, K. and Jarvis, B., Fexofenadine: a review of its use in the management of seasonal allergic rhinitis and chronic idiopathic urticaria. Drugs, 59:301-321, 2000.
3. Shah, V.P., Noory, A., Noory, C., McCullough, B., Clarke, S., Everett, R., Naviasky, H., Srinivasan, B.N., Fortman, D., and Skelly, J.P., In vitro dissolution of sparingly water-soluble drug dosage forms. Int J Pharm, 125:99-106, 1995.
4. Furlanetto, S., Maestrelli, F., Orlandini, S., Pinzauti, S., and Mura, P., Optimization of dissolution test precision for a ketoprofen oral extended-release product. J Pharm Biomed Anal, 32:159-165, 2003.
5. Hofmann, U., Seiler, M., Drescher, S., and Fromm. M.F., Determination of fexofenadine in human plasma and urine by liquid chromatography-mass spectrometry. J Chrom B, 766:227-233, 2002.
6. Gergov, M., Robson, J.N., Ojanperä, I., Heinonen, O.P., and Vuori, E., Simultaneous screening and quantitation of 18 antihistamine drugs in blood by liquid chromatography ionspray tandem mass spectrometry. Forensic Sci Int, 121:108-115, 2001.
7. Fu, I., Woolf, E.J., and Matuszewski, B.K., Determination of fexofenadine in human plasma using 96-well solid phase extraction and HPLC with tandem mass spectrometric detection. J Pharm Biomed Anal, 35: 837-846, 2004.
8. Uno, T., Yasui-Furukori, N., Takahata, T., Sugawara, K., and Tateishi, T., Liquid chromatographic determination of fexofenadine in human plasma with fluorescence detection. J Pharm Biomed Anal, 35:937-942, 2004.
9. Gazy, A.A., Mahgoub, H., El-Yazbi, F.A., El-Sayed, M.A., and Youssef, R.M., Determination of some histamine H1-receptor antagonists in dosage forms. J Pharm Biomed Anal, 30:859-867, 2002.
10. Breier, A.R., Menegola, J., Paim, C.S., Steppe, M., and Schapoval, E.E.S., Development and validation of a liquid chromatographic method for fexofenadine hydrochloride in capsules. J of AOAC Int, 87: 1093-1097, 2004.
11. Radhakrishna, T., and Reddy, G.O. Simultaneous determination of fexofenadine and its related compounds by HPLC. J Pharm Biomed Anal, 24:755-767, 2002.
12. United States Pharmacopoeia, 28th.ed. Rockville, United States Pharmacopoeial Convention, 2005.
13. Marques, M.R.C., and Brown, W., Desenvolvimento e validação de métodos de dissolução para formas farmacêuticas sólidas orais. Revista Analytica, 01:48-51, 2002.
14. Pharmacopeial Forum. Pharmacopeial Previews, 30; (1) [Jan.-Feb. 2004].
15. Costa, P., and Lobo, J.M.S., Modeling and comparison of dissolution profiles. Eur J Pharm Sci, 13:123-133, 2001.
16. Brasil, Resolução-RE no 310, de 1o de setembro de 2004. Anvisa, 2004.
17. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH), Guideline on Validation of Analytical Procedure-Methodology, 1996.
18. Ermer, J., Validation in pharmaceutical analysis, part I, an integrated approach. J Pharm Biomed Anal, 24: 755-767, 2001.
19. Farmacopéia Brasileira, 4th Ed, Ahteneu, Rio de Janeiro, 1988.